NRXP

NRXP

USD

NRX Pharmaceuticals Inc. Common Stock

$2.450-0.220 (-8.240%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$2.670

Haut

$2.700

Bas

$2.440

Volume

0.08M

Fondamentaux de l'Entreprise

Capitalisation Boursière

58.2M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

0.49M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $1.12Actuel $2.450Haut $6.01

Actualités Connexes

Analyst Upgrades

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals with a Buy and maintains $34 price target.

Voir plus
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target
GlobeNewswire

HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health

ONE-D is the first reported protocol to achieve remission from treatment-resistant depression with a single day of treatment, using an FDA-cleared device.HOPE is one of the first Ampa deployments nationwide and is now

Voir plus
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
Analyst Upgrades

Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $47

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals with a Buy and raises the price target from $46 to $47.

Voir plus
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $47
Analyst Upgrades

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals with a Buy and maintains $34 price target.

Voir plus
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target